November 16, 2023.
An editorial published in the journal Alimentary Pharmacology and Therapeutics describes Atmo Biosciences’ gas-sensing capsule as disruptive technology that has enabled unlocking of key aspects of microbial metabolism, especially with respect to carbohydrate fermentation.
November 13, 2023.
Atmo Biosciences is pleased to announce that the Japan Patent Office has granted a patent related to key intellectual property for Atmo’s ingestible gas-sensing capsule.
October 26, 2023.
Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI).
October 19, 2023.
The Atmo Gas Capsule could be used to help understand and monitor duodeno-gastric reflux and provide insight into its connection to delayed gastric emptying, according to an investigation by researchers from Monash University and Western Sydney University.
October 3, 2023.
Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
September 25, 2023.
Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can help diagnose functional gastrointestinal disorders (FGIDs), which affect almost 40 per cent of Australians1.
August 25, 2023.
Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.
August 10, 2023.
Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).
6 July, 2023.
A Monash University clinical study published in the journal Alimentary Pharmacology & Therapeutics1 has found that Atmo Biosciences’ gas-sensing capsule can be used to provide insights into localization of colonic fermentation.
17 May, 2023.
Preliminary results from a University of Queensland (UQ) study to assess how the Atmo Gas Capsule compares to established SIBO (small intestinal bacterial overgrowth) diagnostic methods suggest a good correlation with duodenal aspirate and higher accuracy than a breath test.
Dr Ayesha Shah, a senior lecturer at the UQ School of Medicine, presented data from the study, led by Professor Gerald Holtmann, also from UQ, and Professor Uday Chand Ghoshal of Sanjay Gandhi Postgraduate Institute of Medical Sciences, India, in a presentation at Digestive Disease Week (DDW), held May 6-9 in Chicago.